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SUMMARY 
 
IGHV gene mutational status has prognostic significance in CLL but the percentage of 
mutations which correlates best with clinical outcome remains controversial. We performed IGHV 
gene sequencing on 1018 patients with CLL (558 followed from diagnosis and 460 entered into 
the UK CLL4 trial).   
In the diagnostic cohort, excluding subset #2, significant differences in median TTFT in 
Stage A patients and in OS in the whole cohort, were observed between cases with <97% and 97-
98.99% identity and between cases with 97-98.99% and ≥99% identity. A significant difference in 
PFS and OS was also observed in UK CLL4 trial cases between those with <97% and 97-98.99% 
identity, but not between cases 97-98.99% and ≥99% identity.  
Cox Regression analyses in the Stage A cohort revealed that a model which incorporated 
<97%, 97-98.99%, ≥99% identity as subgroups, was a better predictor of TTFT in CLL than using 
the 98% cut-off. Multivariate analysis selected the three mutational subgroups as independent 
predictors of TTFT in Stage A patients, and of OS in the diagnostic cohort. 
This study highlights that cases with 97% identity should not be considered to have the same 
prognosis as other cases with mutated IGHV genes defined as <98% identity to germline.   
 
Keywords: chronic lymphocytic leukaemia, V-genes, mutation analysis, prognostic factors 
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INTRODUCTION 
In 1999, two studies showed that patients with chronic lymphocytic leukemia (CLL) 
whose immunoglobulin variable region genes (IGHV) had undergone somatic hypermutation 
(SHM) leading to <98% identity to the germline sequence (M-CLL) had a significantly better 
overall survival than patients with 'unmutated' IGHV genes (U-CLL) (Damle et al, 1999; 
Hamblin et al, 1999). Many subsequent retrospective and prospective studies have confirmed 
this observation and shown that IGHV gene mutational status using a 98% cut-off also predicts 
disease progression, time to first treatment and progression free survival. However, the 
mathematical cut-off which correlates best with clinical outcome still remains controversial; 
we and others have previously shown that cut-off's using 97% or 95% identity to the germline 
sequence have clinical relevance and that cases with 97% identity may have an intermediate 
outcome compared to those with <97% or >97% identity (Hamblin et al, 2008; Krober et al, 
2002; Oscier et al, 2010; Tobin et al, 2005).   
The 98% cut-off was originally chosen to avoid scoring polymorphic variants as 
mutations. However, 98% and 99% identity are frequently the consequence of SHM rather 
than polymorphisms (Davis et al, 2003) and even single base changes can affect the binding 
specificity of the B-cell receptor (BcR) (Barbas et al, 1995; Murray et al, 2008). In addition, 
methodological factors such as the choice of PCR primers and immunoglobulin database may 
affect calculation of percentage identity to germline and classification of a case as mutated or 
unmutated. Accordingly, International guidelines recommend caution in assigning mutational 
status and predicted outcome in cases with 'borderline' IGHV identity
 
(Ghia et al, 2007).  
It has also become increasingly clear that other features of the immunoglobulin gene 
sequence, in addition to mutational load, can influence prognosis. In 2002, it was observed 
that usage of the IGHV3-21 gene was an independent unfavourable prognostic marker 
irrespective of IGHV gene mutational status
 
(Tobin et al, 2002). The same group then 
demonstrated that a subset of CLL cases utilising IGHV3-21 had a very short, highly similar, 
if not identical, heavy complementarity-determining region 3 (VH CDR3) and showed biased 
utilisation of the IGLV3-21 gene
 
(Tobin et al, 2003).  In 2004 the term 'stereotyped' BcR was 
introduced that now describes the approximately 30% of CLL cases with similar VH CDR3 
amino acid sequences (Messmer et al, 2004; Darzentas et al, 2010). Many of these stereotypic 
subsets have distinctive biological features such as a characteristic gene expression and 
methylation profile, antigen specificity, immune signaling outcomes, intraclonal 
diversification, immunoglobulin class switching, as well as clinical correlations with genomic 
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copy number abnormalities and mutations, risk of lymphomatous transformation and clinical 
course (Stamatopoulos et al, 2007; Bomben et al, 2009; Marincevic et al, 2010; Rossi et al, 
2009; Sutton et al, 2009; Chu et al, 2010; Kanduri et al, 2012; Ntoufa et al, 2012; Strefford et 
al, 2013; Baliakis et al, 2014, 2015). 
We have further addressed the clinical significance of borderline IGHV identity in 1018 
CLL patients comprising  a diagnostic cohort with predominantly Binet stage A disease and a 
second cohort entered into the UKCLL4 trial. The outcome of patients with 97% identity was 
comparable to those with 98% identity in both cohorts and distinct from other cases currently 
classified as having M-CLL. 
 
MATERIALS AND METHODS 
Patients 
 Blood samples were obtained with patient consent at or close to diagnosis from 350 patients 
diagnosed at the Royal Bournemouth Hospital (Cohort 1) and 208 patients diagnosed in Siena 
(Cohort 2), and at trial entry from 460 patients entered into the UK LRF CLL4 trial. The diagnosis 
of CLL was based on the revised International Workshop Chronic Lymphocytic 
Leukemia/National Cancer Institute (IWCLL/NCI) guidelines for cases from cohorts 1 and 2 and 
the 1996 NCI guidelines for patients entered into the UK CLL4 trial. The study was approved by 
the local ethics committee of the participating institutions.   
Analysis of IGHV-IGHD-IGHJ gene rearrangements 
IGHV-IGHD-IGHJ gene rearrangements were sequenced as previously described (Hamblin 
et al, 2008). All sequences were aligned to the IMGT/V-QUEST database prior to the recent 
updated version 3.3.0 (20 February 2014) and considered mutated if their percentage identity to 
germline was <98%. As the identification of new IGHV genes and new alleles (Xochelli et al, 
2015) will influence the precise determination of SHM status, all of cohort 1 and CLL4 cases 
identified as having 96-98.99% identity to the germline sequence were re-aligned to the updated 
IMGT/V-QUEST programme version: 3.3.0 (20 February 2014) - IMGT/V-QUEST reference 
directory release: 201414-4 (3 April 2014). Reanalysis of these cases was chosen as any changes 
observed in these patients would potentially affect which mutational subgroup they would be 
assigned to. 
All cases were assessed for stereotypy by comparing IGHV gene usage, CDR3 sequence and 
CDR3 length with the published sequences of the 19 “major” stereotypic subsets (Agathangelidis 
et al, 2012) and assigned to one of these subsets if these criteria were met.  
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Other Prognostic Biomarkers 
Flow cytometric testing for ZAP-70 and CD38 expression, cytogenetic analysis, FISH for 
del(13q), del(11q), del(17p) and trisomy 12 and NOTCH1 and SF3B1 mutation screening were 
performed as previously described (Oscier et al, 2002; Orchard et al, 2004; Oscier et al, 2013).  
Statistical Analysis 
Comparative and statistical analysis was performed using IBM SPSS Statistics 21 Data 
Mining and Statistical Analysis Software (IBM Corp. Armonk, NY USA). For patients in cohorts 
1 and 2, time to first treatment (TTFT) and overall survival (OS) were calculated from date of 
diagnosis to date of first treatment or death respectively and censored if these were not reached. 
For patients entered into the UK CLL4 trial PFS was expressed as time from randomization to 
relapse needing further therapy, progression, or death from any cause, and OS was calculated 
from trial entry to death from any cause. Curves were generated using the method of Kaplan and 
Meier. The relationship between known prognostic markers and TTFT, PFS and OS was assessed 
and p-values were generated using the SPSS software.  
 
RESULTS 
Clinical and Laboratory Features and Cohort Comparison 
Clinical and laboratory findings for the three cohorts are summarised in Table I. Significant 
differences between the cohorts are indicated with an asterisk. The median follow-up was 7.31 
years (range 0-35 years). 687 patients were followed up for >5 years and 304 for >10 years. In 
both cohorts 1 and 2, 90% of patients requiring treatment were treated initially and at relapse with 
an alkylating agent and / or purine analogue, according to guidelines that were current at the time 
of treatment. Patients entered into the UK CLL4 trial were randomised to receive either 
chlorambucil or fludarabine alone or in combination with cyclophosphamide
 
(Catovsky et al, 
2007). Cytogenetic and FISH analysis were carried out prior to treatment in 79% of cohort 1 cases 
and 46% were tested within 2 years of diagnosis. In cohort 2 analyses were carried out at 
diagnosis or prior to treatment and for the CLL4 cohort, analysis was carried out at trial entry 
(pre-treatment), with 67% being within 2 years of diagnosis. 
As no significant differences were observed between cohorts 1 and 2 for any of the 
observations summarised in Table I or in TTFT of stage A cases with either M-CLL (median 273 
and 242 months respectively; p=0.120) or U-CLL (median 54 and 48 months respectively; 
p=0.066), the stage A cases of the two cohorts were combined to give a cohort size of 460 cases – 
the stage A cohort. 
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Influence of mutational load on outcome 
IGHV-IGHD-IGHJ gene analysis was performed on all 1018 cases. To assess the mutational 
cut-off that provided the best predictor of outcome, analysis was initially performed on the stage 
A cohort using TTFT as an endpoint to obviate the effect of varying treatment regimens. We 
carried out Cox regression analysis to determine hazard ratios (HR) for each mutational interval 
differing by 1% from 95% - 100% identities, comparing the TTFT. When compared to cases with 
<95% identity (median TTFT of 273 month), a significant difference in TTFT first occurred at 
97% with a median TTFT of 102 and a HR of 2.2, whereas, the median TTFT and HRs for 98%, 
99% and 100% were 44, 48 and 55 months and 3.7, 4.4 and 4.8 respectively (Table II). This 
analysis suggested that stage A cases could be divided into three subgroups with differing median 
TTFT's based on their mutational status; those with <97% identity having a low risk of a short 
TTFT (HR 0-1.6) , those with 97% identity having an intermediate risk (HR 2.2) - and those with 
≥98% identity having a high risk (HR 3.7-4.8).  
Influence of BCR Stereotypy 
Next, we wished to determine whether the different outcome for Stage A patients with 97% 
identity was a consequence of a differing incidence of major stereotypes, especially stereotypic 
subset #2, which is well documented (Baliakas et al, 2015) and confirmed here (Fig S1) to be 
associated with poor outcome independent of IGHV mutational status and is enriched with cases 
with a low mutational load.  
Within the stage A cohort, 42/460 (9.1%) cases were assigned to one of 14 of the 19 ‘major’ 
stereotypic subsets (Agathangelidis et al, 2012) with the following distribution: low risk subgroup 
- 4.5%, intermediate - 3% and high risk subgroup - 18.2%. Subsets #1 and #2 were the most 
frequently observed stereotypic subsets among the stage A cohort, both accounting for 21% (9/42) 
each of all stereotypic cases.  
Cox regression analysis for each mutational interval (95-100%) was initially repeated 
excluding all major stereotype cases, and now the HR and the median TTFT for cases with 97% 
and 98% were very similar; with a median TTFT of 102 and 105 months and HRs of 2.3 and 2.6 
respectively (Table III).  Secondly, because 4/5 stereotypic cases with 97% or 98% identity 
belonged to subset #2, analysis was repeated with the exclusion of this subset only. The HR and 
TTFT’s of the 97% and 98% identity cases remained very similar or the same (HRs 2.2 and 2.9, 
TTFT 102 and 105 months respectively) as the previous analysis when all major stereotypes were 
excluded, indicating that the effect of stereotypy on TTFT was a consequence of subset #2. 
Exclusion of subset #2 enabled the remaining cases to be divided into 3 risk groups: 1) low risk 
HR - 1 (<97%), 2) intermediate risk HR - 2.3 (97-98.99%) and 3) high risk HR - 4.3(≥99%).  
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We then carried out proportional hazard analysis without subset #2 cases, comparing the 
standard cut-off (98%) to either a model with 97% as the cut-off or the 3 mutational subgroup 
model (<97%, 97-98.99% and ≥99%). We found no difference in the models using either 98% or 
97% as a cut-off (p=0.338) but the 3 subgroup model showed a significant improvement at 
predicting TTFT than both of these models (p=0.005 and p=0.003 respectively).  
Kaplan Meier survival curves and the median TTFT for stage A cases were then determined 
for the 3 subgroup model without subset #2. Of note there was a significant difference in TTFT 
between <97% and 97-98.99% (median TTFT not reached and 105 months respectively; p<0.001) 
and between 97-98.99% and ≥99% (105 and 52 months; p=0.002) (Fig 1A). 
When this model was applied to cohorts 1 and 2, including those with Binet stage B and C 
disease, to assess OS, a significant difference was observed between each of the three subgroups; 
with a median OS of 231, 141 and 111 months respectively (p=0.003 and p=0.005) (Fig 1B). 
UK CLL4 cohort 
Within the CLL4 cohort 96/460 (20.9%) cases were assigned to 18/19 major stereotypic 
subsets; subset #2 constituted 36.5% (35/82) of all stereotypic cases and 25/35 had an 
intermediate identity of 97% or 98%. In light of this, subset #2 cases were once again excluded 
from analysis when the three subgroup model was assessed in the CLL4 cohort. 
Initially, proportional hazard model analysis was repeated in the CLL4 cohort using PFS as 
the predictor of outcome. Again a significant improvement in predicting outcome was observed 
when using the three mutational subgroups over the current 98% cut-off (p=0.003), regardless of 
whether treatment arm was included in the analysis (p<0.001).   
Kaplan Meier survival curves and median survival times were then determined using the 3 
mutational subgroups. A significant difference was noted between PFS of cases with <97% 
identity and those with 97-98.99%, (median PFS 42 and 30 months respectively; p<0.001) 
however, significance was not reached between those with 97-98.99% and those with ≥99% 
(median PFS 20; p=0.124) (Fig 1C). Similarly, a significant difference in OS was observed 
between cases with <97% identity and those with 97-98.99% (p<0.001), with a median OS of 121 
months and 62 months respectively, but not between those with 97-98.99% and ≥99% (median 
OS 61 months; p=0.323) (Fig 1D) 
Multivariate survival analyses  
Multivariate survival analyses were then performed in models that included the following 
parameters: age at diagnosis, gender, CD38 and ZAP 70 positivity, del(13q), trisomy 12, del(11q), 
del(17p), NOTCH1 and SF3B1 mutation and treatment arm. Tables SI and SII highlight which 
biomarkers were significant in univariate analysis for either TTFT in the stage A cohort, PFS in 
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CLL4 or OS for cohorts 1 and 2, and CLL4. The three subgroup model emerged as an 
independent predictor of TTFT in the stage A cohort, together with del(11q) and age at diagnosis, 
and also as an independent marker of OS together with age at diagnosis, CD38 expression and 
del(17p) in all cases from cohorts 1 and 2 (Table IV). The analyses were then repeated using the 
intermediate subgroup (97-98.99% identity) as the reference category to confirm the independent 
significance of each mutational subgroup, and all the above factors remained significant 
independent predictors of TTFT and OS respectively (Table SIII).   
Multivariate survival analyses of the CLL4 cohort showed that the three mutational subgroup 
model was an independent predictor of PFS, together with del(11q), del(17p) and treatment type, 
and of OS, together with age, gender, CD38, del(11q) and del(17p) (Table V). When analyses was 
repeated using the intermediate subgroup (97-98.99% identity) as the reference category, 
significance was lost for the high risk subgroup (≥99% identity) for both PFS and OS (Table SIV). 
Investigation of other factors that might account for the intermediate outcome of cases with 
97.0 to 98.99% identity 
Methodological factors 
We initially sought to exclude the possibility that the intermediate TTFT of cases with 97-
98.99% identity reflected the calculation of IGHV gene mutational load when different PCR 
primers were used for analysis. Seventy percent of cohorts 1 and 2 were amplified with leader 
primer and TTFT and OS analysis of the three mutational subgroups based on, only those cases 
amplified using the leader primer did not change the statistically significant differences between 
the three subgroups. 
In addition, as a result of the recent update to the IMGT/V-QUEST reference directory, 
available sequences with borderline identities across the subgroups (152/204 96-98.99%) were 
reanalysed using IMGT/V-QUEST v.3.3.0 reference directory release: 201414-4 (3 April 2014) 
which includes all newly identified IGHV genes and alleles. Only 1/152 sequences from a patient 
with Binet stage C disease in the combined cohorts 1 and 2 changed from 98% to 99% identity. 
Analysis of OS in cohorts 1 and 2 was repeated with no significant changes observed; these 
reanalysed results are shown in Figure 1B.  
Finally, the frequency of polymorphisms was assessed in 6 cases with 97% identity utilising 
IGHV3-23 by comparing the CLL IGHV gene sequence with its corresponding germline sequence. 
All genomic variations classified as mutations based on the CLL sequence were confirmed as 
mutations. 
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IGHV Gene Usage  
IGHV gene use differed among the three mutational subgroups (Table SV). To determine 
whether the intermediate outcome of cases with 97-98.99% identity is due to the biased use of 
specific IGHV genes, we focused on stage A cases using the IGHV3-23 gene, the most frequently 
utilised gene in the intermediate subgroup. TTFT was reanalysed excluding cases utilising 
IGHV3-23 and the significant difference in TTFT between the intermediate risk group and both 
the low and high risk groups persisted (p=0.001 and p=0.001 respectively).  
In addition, when IGHV3-23 cases alone were assessed using the three subgroup model, 
TTFT was significantly shorter for IGHV3-23 cases in the intermediate subgroup (median TTFT 
45 months; p=0.022) compared to those with <97% (median TTFT 273 months).  These results 
support the conclusion that IGHV gene usage alone is unlikely to account for the intermediate 
TTFT of 97%-98.99% identity cases. 
SF3B1 and NOTCH1 mutations 
As SF3B1 and NOTCH1 mutations have adverse prognostic significance in CLL and their 
incidence differs between M-CLL and U-CLL and among stereotypic subsets, we compared the 
incidence of these mutations among the 3 mutational risk groups (Strefford et al, 2013; Oscier et 
al, 2013; Rossi et al, 2011). SF3B1 and NOTCH1 mutation status was available for 315 CLL4 
cases and for 159 cohort 1 cases (excluding subset #2 cases). Of note the incidence of SF3B1 
mutated cases was significantly higher in the intermediate subgroup than the low risk group (27% 
and 5% respectively; p=<0.001) and there was also a trend towards a higher incidence in the 
intermediate group than in the high risk group (15%; p=0.0564). The incidence of NOTCH1 
mutated cases was significantly less in the low risk subgroup than in the high risk subgroup (1% 
and 13% respectively; p<0.001) but the incidence in the intermediate subgroup (6%) was not 
significantly different from either of the other subgroups.  
There were too few cases in each of the subgroups to carry out survival analysis in the stage 
A cohort, but as highlighted earlier SF3B1 and NOTCH1 did not show independent significance in 
multivariate analysis in the CLL4 cohort. 
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DISCUSSION  
This is the largest study to address the optimal cut-off for IGHV identity to the germline 
sequence which correlates best with clinical outcome. The analysis was based on IGHV gene 
sequence data from 1018 well characterised patients with CLL who were either studied from time 
of randomisation into the UK CLL4 trial (Catovsky et al, 2007) (n=460) or who presented in 
Bournemouth or Siena (n=558) predominantly with Binet Stage A disease (n=460).  As there were 
no significant differences in IGHV gene mutation status and usage, biomarker results, 
demographics and TTFT between Stage A patients presenting in Bournemouth or Siena, nor in the 
indications for, and type of treatments used in each centre, data from both centres were analysed 
as a single cohort. 
Initial analysis of TTFT in the stage A cohort suggested that patients with 97% identity had 
an intermediate outcome between those with <97% and >97% identity. When cases with  
stereotyped subset #2 were excluded due to their known association with poor outcome and higher 
incidence among cases with a low mutational load (Baliakis et al, 2014, 2015), we then observed 
that the median TTFT in patients presenting with Stage A disease was comparable for patients 
with either 97% or 98% identity, and that cases could still be subdivided into 3 risk groups: a low 
risk group (<97% identity), an intermediate risk group (97-98.99% identity) and a high risk group 
(≥99% identity) each with a successively significant shorter TTFT. This 3 mutational group model 
emerged as an independent predictor of TTFT and of OS in the Bournemouth/Siena patients in 
multivariate analyses which included significant variables identified in univariate analysis (age, 
expression of CD38 and ZAP70 and cytogenetic abnormalities). 
In the UK CLL4 trial cohort, again excluding stereotyped subset #2, cases with 97-98.99% 
identity had a significantly shorter PFS and OS than those with <97% identity but there was no 
difference between the 97-98.99% and ≥99% groups. Multivariate analyses showed that the 3 
mutational group model was an independent predictor of PFS and OS only when <97% identity 
cases (but not 97-98.99% identity cases) were used as the reference category. 
U-CLL and M-CLL, defined by using 98% identity as a cut-off, are widely considered to 
arise from two distinct subsets of normal B cells at different stages of differentiation. The 
differing consequences of engagement of the BcR by antigen within the CLL microenvironment 
(Stevenson et al, 2011; Packham et al, 2014)
 
in these subsets exerts a strong influence on clinical 
outcome. Although it is well recognised that there is both biological and clinical heterogeneity 
within the 2 mutational subsets, especially M-CLL (Oscier et al, 2010; Pflug et al, 2014; Rassenti 
et al, 2008; Bulian et al 2014; Pepper et al, 2015; Rossi et al, 2009; Paterson et al, 2012), one 
implication of this two-subset model is that cases with 97% identity might be expected to show 
Page 10 of 22British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
greater clinical similarity to cases with higher mutational loads than to cases with 98% identity. 
Data from our cohorts strongly suggest that the outcome of patients with 97% identity is more 
similar to those with 98% identity than to those with greater IGHV mutational loads. We could 
identify neither methodological nor biological factors to account for the poorer outcome of cases 
with 97% identity compared to those with <97% identity, although the higher incidence of SF3B1 
mutations in the intermediate risk group, even without stereotypic subset #2 cases, is of interest 
and requires confirmation in a larger cohort.  
Recently an epigenetic signature based on the methylation status of 5 CpG sites has been 
identified which reliably classified CLL cases into 3 clusters with differing clinical outcomes. The 
authors postulated that the intermediate methylation cluster, which is enriched with cases having a 
low IGHV mutational load, might reflect CLL cases derived from an antigen-experienced, 
germinal centre-independent marginal zone B cell (Queirós et al, 2015). A recent, subsequent 
study integrated this epigenetic data with genomic data and noted higher frequencies of SF3B1 
and MYD88 mutations, biased usage of IGVH3-21 and IGHV1-18 genes and of stereotypic subset 
#2 in the intermediate methylation cluster (Puente et al, 2015). 
In summary, regardless of the mechanisms by which IGHV mutational load influences the 
biology of CLL, our results add weight to previous studies suggesting that cases with 97% identity 
should not be considered to have the same prognosis as other cases with mutated IGHV genes 
defined as <98% identity to germline and this may be especially useful in the prognostic 
evaluation of patients with Stage A disease. In addition, although stereotypic subset analysis is 
important in defining clinically relevant subgroups, approximatley 70% of cases cannot be 
assigned to a stereotype and refining mutational status analysis will provide valuable clinical 
information for these patients. Finally, although our study is large in comparison to previous 
studies, only 11.5% of cases had 97-98.99% identity and additional larger studies will be required 
both to confirm our findings in patients presenting with Stage A disease and establish whether the 
3 risk groups have prognostic significance in patients requiring treatment. 
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TABLES 
Table I. Frequencies of clinical characteristics for the three cohorts  
 
Variable 
Cohort 1 
N (%) 
Cohort 2 
N (%) 
UK LRF CLL4 
N (%) 
Total cases 350 208 460 
Total requiring treatment during follow up*  159  (51) 107  (51) 460  (100) 
Male* 222  (63) 126  (61) 339  (74) 
Female 127  (36) 82  (39) 118  (26) 
Median age at diagnosis (years)* 65.0 66.0 62.7 
Binet Stage*       
A 290  (83) 170  (82) 121  (26) 
B 43  (12) 24  (12) 203  (44) 
C 17  (5) 14  (7) 136  (30) 
IGHV unmutated* 138  (39) 91  (44) 284  (62) 
Mutated (<98%) 212  (61) 117  (56) 176  (38) 
Total IGHV3-21  11  (3) 10  (5) 40  (9) 
Total Subset #2* 8  (2) 5  (2) 35  (8) 
del(11q) -ve 285  (86) 181 (91) 332 (78) 
             +ve* 45 (14) 19  (10)  94  (22) 
del(17p) -ve 303 (93) 189 (94) 398 (94) 
              +ve 23 (7) 12 (6) 25 (6) 
No significant differences were observed between cohorts 1 and 2 
* Variables where UK LRF CLL4 cases show a significant difference to cohorts 1 and 2 
 
Table II. Cox proportional hazard and Kaplan Meier survival analysis of TTFT in stage A cohort 
Time to First Treatment (months) 
% Identity  
boundaries 
Total Events Median 95% CI HR 95% CI P 
≤94.99 188 47 273  1  ref 
95-95.99 36 10 Not reached - 0.8 0.4-1.7 0.610 
96-96.99 28 10 Not reached - 1.6 0.8-3.2 0.184 
97-97.99 32 15 102 81.9-122.2 2.2 1.2-4.0 0.007
* 
98-98.99 17 11 44 8.3-79.3 3.7 1.9-7.2 <0.001 
99-99.99 24 15 48 19.4-76.7 4.4 2.4-7.9 <0.001 
100% 103 68 55 40.4-68.8 4.8 3.3-7.0 <0.001 
Cases with % identity of ≤94.99 were used as the reference category. 
 
Table III. Cox proportional hazard and Kaplan Meier survival analysis of TTFT in stage A cohort 
without stereotypic cases 
Time to First Treatment (months) 
% Identity  
boundaries 
Total Events Median 95% CI HR 95% CI P 
≤94.99 182 44 Not reached  1  ref 
95-95.99 33 9 Not reached - 0.9 0.4-1.8 0.733 
96-96.99 26 9 Not reached - 1.6 0.8-3.3 0.193 
97-97.99 31 15 102 81.9-122.2 2.3 1.3-4.1 0.006
* 
98-98.99 13 7 105 22.8-187.1 2.6 1.2-5.8 0.018 
99-99.99 19 11 48 29.2-67.7 3.9 2.0-7.6 <0.001 
100% 84 52 60 33.9-86.1 4.5 3.0-6.8 <0.001 
Cases with % identity of ≤94.99 were used as the reference category. 
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Table IV. Multivariate Cox proportional hazard analysis of TTFT (Stage A cohort) and OS (All 
cases cohorts 1 & 2). 
 Stage A Cohort  
Time to First Treatment (months) 
All Cases from Cohorts 1 & 2  
Overall Survival (months) 
Variable HR 95% CI P HR 95% CI P 
<97% identity (ref. category) 1  <0.001 1  <0.001 
97&98% identity 2.46 1.42-4.26 0.001 2.17 1.30-3.61 0.003 
99&100% identity 4.98 3.21-7.74 <0.001 4.39 2.84-6.79 <0.001 
Age at Diagnosis 0.98 0.97-0.99 0.009 1.08 1.06-1.10 <0.001 
CD38 1.31 0.83-1.08 0.25 1.50 1.02-2.22 0.040 
ZAP70 0.76 0.47-1.23 0.27 0.83 0.53-1.29 0.40 
del(11q) 3.09 1.81-5.26 <0.001 1.40 0.89-2.20 0.14 
Trisomy 12 1.10 0.68-1.78 0.69 - - - 
del(17p) - - - 3.05 1.72-5.42 <0.001 
- Variables not significant in Univariate analysis were not included in multivariate analysis. 
TTFT Multivariate: 320 cases with 131 events; 131 cases with missing data. OS Multivariate: 397 cases with 
156 events; 136 cases with missing data. 
 
 
Table V. Multivariate Cox proportional hazard analysis of PFS and OS in the LRF CLL4 cases 
 Progression Free Survival (months) Overall Survival (months) 
Variable HR 95% CI p HR 95% CI p 
<97% identity (ref. category) 1  <0.001 1  0.005 
97&98% identity 2.51 1.60-3.95 <0.001 2.61 1.36-5.01 0.004 
99&100% identity 2.50 1.70-3.68 <0.001 2.43 1.34-4.40 0.003 
Age at Diagnosis - - - 1.05 1.03-1.07 <0.001 
Gender 1.22 0.90-1.66 0.19 1.99 1.28-3.11 0.002 
CD38 1.12 0.86-1.45 0.40 1.24 0.84-1.81 0.28 
ZAP70 1.06 0.79-1.43 0.70 0.79 0.52-1.19 0.26 
del(13q) 0.94 0.72-1.24 0.66 1.14 0.76-1.69 0.53 
del(11q) 1.67 1.24-2.25 0.001 1.55 1.02-2.36 0.04 
del(17p) 4.75 2.91-7.74 <0.001 7.53 3.34-16.99 <0.001 
NOTCH 1 - - - 1.66 0.97-2.87 0.07 
SF3B1 - - - 1.35 0.85-2.17 0.21 
Tx FDR (ref. category) 1  <0.001 - - - 
Tx Chl 2.72 1.99-3.73 <0.001 - - - 
Tx FC 1.98 1.41-2.79 <0.001 - - - 
- Variables not significant in Univariate analysis were not included in multivariate analysis. 
PFS Multivariate: 299 cases with 274 events; 126 cases with missing data. OS Multivariate: 199 cases with 145 
events; 226 cases with missing data. 
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FIGURE LEGEND 
 
Figure 1. Outcome of patients with <97%, 97-98.9% and ≥99% identity to germline.  
The P value is derived from Kaplan-Meier analysis and median survival times with 95% 
confidence intervals. 
(A) Stage A cohort: time to first treatment.  (B) Cohorts 1 & 2: overall survival. (C) CLL4 
cohort: progression free survival.  (D) CLL4 cohort: overall survival. 
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Supplemental Table I. Univariate analysis of TTFT (Stage A cohort) and OS (All cases cohorts 1 & 2) 
 Stage A Cohort  
Time to First Treatment (months) 
All Cases from Cohorts 1 & 2  
Overall Survival (months) 
 Biomarker Total Events Median 95% CI P Total Events Median 95% CI P 
Clinical 
feature 
Age  428 176   <0.001 540 221   <0.001 
 Sex Male 256 105 129.2 92.6-165.8  345 135 155.8 117.1-194.5  
  Female 172 71 152.3 70.7-233.9 NS 207 86 161.2 136.0-186.4 NS 
Biomarker CD38  -ve 310 110 231.9 137.0-326.9  379 122 200.0 166.9-233.2 
 
  +ve 83 49 74.9 52.4-97.5 0.001 118 67 111.3 87.6-135.0 <0.001 
 ZAP70 -ve 305 113 169.9 90.3-249.6  369 125 199.4 181.1-217.8  
  +ve 64 45 60.4 29.7-91.1 <0.001 96 54 115.4 100.2-130.6 <0.001 
 Del(13q) Yes 206 82 155.7 60.6-250.9  249 116 155.5 127.4-183.6  
  no 167 67 141.0 82.8-199.1 NS 204 76 169.0 125.5-212.5 NS 
 Tri12 Yes 78 39 80.8 25.8-135.7  98 45 141.4 114.0-168.7  
  no 296 119 155.7 83.1-228.4 0.041 369 150 177.9 149.0-206.9 NS 
 Del(11q) Yes 38 27 37.5 17.1-58.0  64 38 99.0 66.3-131.7  
  no 378 146 152.3 91.0-213.6 <0.001 462 169 184.3 156.4-212.3 <0.001 
 Del(17p) Yes 20 10 103.0 22.9-183.1  34 18 102.9 52.6-153.1  
  No 395 164 131.4 81.2-181.5 NS 489 188 166.7 141.5-191.8 0.003 
 
Supplemental Table II. Univariate analysis of PFS and OS in the LRF CLL4 cases 
 UK LRF CLL4 Trial  
Progression Free Survival  (months) 
UK LRF CLL4 Trial 
Overall Survival (months) 
 Biomarker Total Events Median 95% CI P Total Events Median 95% CI P 
Clinical feature Age  460 424   NS 460 332   <0.001 
 Sex Male 339 316 23.2 19.8-26.6  339 260 69.0 60.3-77.7  
  Female 118 105 30.0 23.5-36.4 0.011 118 71 87.1 70.7-103.5 0.001 
Biomarker CD38  -ve 205 182 28.6 22.8-34.4  205 128 94.5 81.5-107.5 
 
  +ve 177 170 18.9 15.8-21.9 <0.001 177 148 55.7 47.8-63.7 <0.001 
 ZAP70 -ve 195 168 31.5 26.6-36.4  195 124 86.9 72.0-102.0  
  +ve 217 210 20.7 18.1-23.2 <0.001 217 175 67.1 57.6-76.7 <0.001 
 Del(13q) Yes 246 220 23.7 18.6-28.8  246 164 78.7 69.7-87.9  
  no 177 171 23.3 18.8-27.7 0.025 177 145 57.0 46.0-68.1 <0.001 
 Tri12 Yes 66 62 19.5 13.3-25.9  66 53 53.6 30.4-76.7  
  no 357 329 23.9 21.0-26.8 NS 357 256 73.0 65.1-80.9 NS 
 Del(11q) Yes 94 90 17.1 14.4-19.7  94 79 55.6 40.4-70.9  
  no 332 304 26.7 22.9-30.5 0.001 332 233 75.0 66.3-83.8 0.001 
 Del(17p) Yes 25 25 3.7 2.6-4.8  25 24 18.3 0.7-35.9  
  No 398 366 25.0 21.4-28.5 <0.001 398 285 74.6 67.4-81.9 <0.001 
Gene mutations NOTCH1 WT 304 280 25.7 22.2-29.1  304 221 77.0 69.7-84.4  
  Mut 32 31 22.0 16.0-28.1 NS 32 29 53.4 31.3-75.5 0.005 
 SF3B1 WT 263 234 23.9 19.6-28.2  263 179 79.0 69.7-88.3  
  Mut 52 52 26.1 22.3-29.8 NS 52 47 59.3 44.8-73.8 0.003 
Treatment Arm Chl  223 213 20.0 17.0-23.1  223 160 77.0 69.1-84.9  
 FC  118 111 21.9 17.1-26.8  118 86 66.5 50.0-83.0  
 FDR  119 100 40.6 33.0-48.2 <0.001 119 86 70.8 50.8-90.7 NS 
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Supplemental Table III. Multivariate Cox proportional hazard analysis of TTFT (Stage A cohort) and OS (All 
cases cohorts 1 & 2) using the intermediate percentage identity subgroup as the reference category.   
 Stage A Cohort  
Time to First Treatment (months) 
All Cases from Cohorts 1 & 2  
Overall Survival (months) 
Variable HR 95% CI P HR 95% CI P 
97&98% identity (ref. category) 1  <0.001 1  <0.001 
<97% identity 0.41 0.24-0.71 0.001 0.46 0.28-0.77 0.003 
99&100% identity 2.03 1.18-3.48 0.010 2.03 1.21-3.39 0.007 
Age at Diagnosis 0.98 0.97-1.0 0.009 1.08 1.06-1.10 <0.001 
CD38 1.31 0.83-2.08 0.25 1.50 1.02-2.22 0.040 
ZAP70 0.76 0.47-1.23 0.27 0.83 0.53-1.29 0.40 
del(11q) 3.09 1.81-5.26 <0.001 1.40 0.89-2.22 0.14 
Trisomy 12 1.10 0.68-1.78 0.69 - - - 
del(17p) - - - 3.05 1.72-5.42 <0.001 
- Variables not significant in Univariate analysis were not included in multivariate analysis. 
TTFT Multivariate: 320 cases with 131 events; 131 cases with missing data. OS Multivariate: 397 cases with 156 events; 136 
cases with missing data. 
 
Supplemental Table IV. Multivariate Cox proportional hazard analysis of PFS and OS in the LRF CLL4 cases 
using the intermediate percentage identity subgroup as the reference category. 
 Progression Free Survival (months) Overall Survival (months) 
Variable HR 95% CI p HR 95% CI p 
97&98% identity (ref. category) 1  <0.001 1  0.005 
<97% identity 0.40 0.25-0.63 <0.001 0.38 0.20-0.74 0.004 
99&100% identity 1.0 0.68-1.47 0.98 0.93 0.53-1.64 0.81 
Age at Diagnosis - - - 1.05 1.03-1.07 <0.001 
Gender 1.22 0.90-1.66 0.19 1.99 1.28-3.11 0.002 
CD38 1.12 0.86-1.45 0.40 1.24 0.84-1.81 0.28 
ZAP70 1.06 0.79-1.43 0.70 0.79 0.52-1.19 0.26 
del(13q) 0.94 0.72-1.24 0.66 1.14 0.76-1.69 0.53 
del(11q) 1.67 1.24-2.25 0.001 1.55 1.02-2.36 0.040 
del(17p) 4.75 2.91-7.74 <0.001 7.53 3.34-16.99 <0.001 
NOTCH 1 - - - 1.66 0.97-2.87 0.07 
SF3B1 - - - 1.35 0.85-2.17 0.21 
Tx FDR (ref. category) 1  <0.001 - - - 
Tx Chl 2.72 1.99-3.73 <0.001 - - - 
Tx FC 1.98 1.41-2.79 <0.001 - - - 
- Variables not significant in Univariate analysis were not included in multivariate analysis. 
PFS Multivariate: 299 cases with 274 events; 126 cases with missing data. OS Multivariate: 199 cases with 145 events; 226 cases 
with missing data. 
 
Supplemental Table V. The most frequently utilised IGHV genes in the three mutational subgroups (excluding 
subset #2). 
Low Risk Subgroup <97%  identity 
(n=412) 
Intermediate Risk Subgroup 97-
98.99% identity (n=117) 
High Risk Subgroup ≥99% identity 
(n=441) 
IGHV3-7 – 35 (8.5%) IGHV3-11 – 7 (6.0%) IGHV1-2 – 38 (8.6%) 
IGHV3-23 – 57 (13.8%) IGHV3-23 – 23 (19.7%) IGHV1-69 – 133 (30.2%) 
IGHV4-34 – 64 (15.5%) IGHV3-48 – 11 (9.4%)  
3/41 genes accounting for 37.8% 3/35 genes accounting for 35.1% 2/43 genes accounting for 38.8% 
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Figure Legends. 
Supplemental Figure 1. Kaplan-Meier analysis of time to first treatment of whole cohort (1018 cases) when 
grouped as: IGHV unmutated, IGHV mutated, stereotypic subset #2 unmutated and stereotypic subset #2 
mutated, using a 98% cut-off. 
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